TY - JOUR
T1 - Treating irritable bowel syndrome
T2 - Overview, perspective and future therapies
AU - Camilleri, Michael
PY - 2004/4
Y1 - 2004/4
N2 - This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.
AB - This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.
KW - Challenges
KW - Colonic diseases
KW - Functional
KW - Opportunities
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=2442581507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442581507&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0705741
DO - 10.1038/sj.bjp.0705741
M3 - Review article
C2 - 15037521
AN - SCOPUS:2442581507
SN - 0007-1188
VL - 141
SP - 1237
EP - 1248
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 8
ER -